石藥集團(01093.HK):高選擇性FGFR4抑制劑“SYHX2005”獲臨牀試驗許可
格隆匯4月26日丨石藥集團(01093.HK)發佈公吿,集團開發的“SYHX2005”已獲得中國國家藥品監督管理局批准,可以在中國開展臨牀試驗。該產品為集團研發的化藥1類新藥,已在國內外申請多項專利。該產品是一種高選擇性FGFR4抑制劑,目前全球尚無同類產品上市,本次獲批臨牀試驗的適應症為晚期實體瘤。臨牀前研究顯示,該產品藥效靶點選擇性高,具有優異的體內外活性和良好的安全性,極具臨牀開發價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.